Overexpression of heparan sulfate 6‑O‑sulfotransferase‑2 in colorectal cancer

Hatabe,Shigeru; Kimura,Hideharu; Arao,Tokuzo; Kato,Hiroaki; Hayashi,Hidetoshi; Nagai,Tomoyuki; Matsumoto,Kazuko; De Velasco,Marco; Fujita,Yoshihiko; Yamanouchi,Go; Fukushima,Masao; Yamada,Yasuhide; Ito,Akihiko; Okuno,Kiyotaka; Nishio,Kazuto

doi:10.3892/mco.2013.151

Overexpression of heparan sulfate 6‑O‑sulfotransferase‑2 in colorectal cancer

Authors:
- Shigeru Hatabe
- Hideharu Kimura
- Tokuzo Arao
- Hiroaki Kato
- Hidetoshi Hayashi
- Tomoyuki Nagai
- Kazuko Matsumoto
- Marco De Velasco
- Yoshihiko Fujita
- Go Yamanouchi
- Masao Fukushima
- Yasuhide Yamada
- Akihiko Ito
- Kiyotaka Okuno
- Kazuto Nishio
View Affiliations

Affiliations: Department of Surgery, Kinki University School of Medicine, Osaka‑Sayama, Osaka 589‑8511, Japan, Department of Genome Biology, Kinki University School of Medicine, Osaka‑Sayama, Osaka 589‑8511, Japan, Sumitomo Bakelite Co., Ltd., Nishi‑ku, Kobe 651‑2241, Japan, Department of Medical Oncology, National Cancer Center Hospital, Chuo‑ku, Tokyo 104‑0045, Japan, Department of Pathology, Kinki University School of Medicine, Osaka‑Sayama, Osaka 589‑8511, Japan
Published online on: July 23, 2013 https://doi.org/10.3892/mco.2013.151
Pages: 845-850

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The heparan sulfate sulfotransferase gene family catalyzes the transfer of sulfate groups to heparan sulfate and regulates various growth factor‑receptor signaling pathways. however, the involvement of this gene family in cancer biology has not been elucidated. It was demonstrated that the heparan sulfate D‑glucosaminyl 6‑O‑sulfotransferase‑2 (HS6ST2) gene is overexpressed in colorectal cancer (CRC) and its clinical significance in patients with CRC was investigated. The mRNA levels of HS6ST2 in clinical CRC samples and various cancer cell lines were assessed using a microarray analysis and quantitative RT‑PCR, respectively. An immunohistochemical (IHC) analysis of the HS6ST2 protein was performed using 102 surgical specimens of CRC. The correlations between the HS6ST2 expression status and clinicopathological characteristics were then evaluated. HS6ST2 mRNA was significantly overexpressed by 37‑fold in CRC samples compared to paired colonic mucosa. High levels of HS6ST2 mRNA expression were also observed in colorectal, esophageal and lung cancer cell lines. the IHC analysis demonstrated that HS6ST2 was expressed in the cytoplasmic region of CRC cells, but not in normal colonic mucosal cells. Positive staining for HS6ST2 was detected in 40 patients (39.2%). There was no significant association between the clinicopathological characteristics and HS6ST2 expression. However, positive staining for HS6ST2 was associated with a poor survival (P=0.074, log‑rank test). In conclusion, HS6ST2 was found to be overexpressed in CRC and its expression tended to be a poor prognostic factor, although the correlation was not significant. These findings indicate that HS6ST2 may be a novel cancer‑related marker that may provide insight into the glycobiology of CRC.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kaneda H, Arao T, Tanaka K, et al: FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res. 70:2053–2063. 2010. View Article : Google Scholar : PubMed/NCBI
3	Sasisekharan R, Shriver Z, Venkataraman G and Narayanasami U: Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer. 2:521–528. 2002. View Article : Google Scholar : PubMed/NCBI
4	Sanderson RD: Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 12:89–98. 2001. View Article : Google Scholar : PubMed/NCBI
5	Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, et al: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 61:5562–5569. 2001.PubMed/NCBI
6	Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al: Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 88:12–20. 2000. View Article : Google Scholar : PubMed/NCBI
7	Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH and Kimata K: Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem. 279:12346–12354. 2004. View Article : Google Scholar : PubMed/NCBI
8	Pye DA, Vives RR, Turnbull JE, Hyde P and Gallagher JT: HS oligosaccharides require 6-O-sulphation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem. 273:22936–22942. 1998.PubMed/NCBI
9	Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL and Gallagher JT: Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes. J Biol Chem. 280:42274–42282. 2005. View Article : Google Scholar : PubMed/NCBI
10	Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K and Emerson CP Jr: Substrate specificity and domain functions of extracellular heparin sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem. 281:4969–4976. 2006. View Article : Google Scholar : PubMed/NCBI
11	Labbé E, Lock L, Letamendia A, et al: Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res. 67:75–84. 2007.PubMed/NCBI
12	Backen AC, Cole CL, Lau SC, et al: Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer. 96:1544–1548. 2007. View Article : Google Scholar : PubMed/NCBI
13	Song K, Li Q, Peng YB, Li J, Ding K, et al: Silencing of hHS6ST2 inhibits progression of pancreatic cancer through inhibition of Notch signalling. Biochem J. 436:271–282. 2011. View Article : Google Scholar : PubMed/NCBI
14	Pollari S, Käkönen RS, Mohammad KS, et al: Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res. 10:597–604. 2012. View Article : Google Scholar : PubMed/NCBI
15	Esko JD and Selleck SB: Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 71:435–471. 2002. View Article : Google Scholar : PubMed/NCBI
16	Persimmon N and Bernfield M: Specificities of heparan sulfate proteoglycans in developmental processes. Nature. 404:725–728. 2000. View Article : Google Scholar
17	Nakato H and Kimata K: Heparan sulfate fine structure and specificity of proteoglycan functions. Biochem Biopsy Acta. 1573:312–318. 2002. View Article : Google Scholar : PubMed/NCBI
18	Chen E, Stringer SE, Rusch MA, Selleck SB and Ekker SC: A unique role for 6-O sulfation modification in zebrafish vascular development. Dev Biol. 284:364–376. 2005.
19	Lundin L, Larsson H, Kreuger J, Kanda S, Lindahl U, Salmivirta M and Claesson-Welsh L: Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J Biol Chem. 275:24653–24660. 2000. View Article : Google Scholar : PubMed/NCBI
20	Nagai N, Habuchi H, Esko JD and Kimata K: Stem domains of heparan sulfate 6-O-sulfotransferase are required for Golgi localization, oligomer formation and enzyme activity. J Cell Sci. 117:3331–3341. 2004.PubMed/NCBI